| __timestamp | Alnylam Pharmaceuticals, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 12122000 |
| Thursday, January 1, 2015 | 276495000 | 13380000 |
| Friday, January 1, 2016 | 382392000 | 21221000 |
| Sunday, January 1, 2017 | 390635000 | 26887000 |
| Monday, January 1, 2018 | 505420000 | 27863000 |
| Tuesday, January 1, 2019 | 655114000 | 55908000 |
| Wednesday, January 1, 2020 | 654819000 | 59392000 |
| Friday, January 1, 2021 | 792156000 | 69012000 |
| Saturday, January 1, 2022 | 883015000 | 36082000 |
| Sunday, January 1, 2023 | 1004415000 | 24537000 |
| Monday, January 1, 2024 | 1126232000 |
Igniting the spark of knowledge
In the ever-evolving world of biopharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have demonstrated contrasting approaches to R&D investment. Alnylam's R&D expenses have surged by over 400% from 2014 to 2023, reflecting its commitment to pioneering RNA interference therapeutics. In contrast, Ligand's R&D spending has remained relatively stable, peaking in 2021 with a modest increase of around 470% from its 2014 baseline.
This divergence highlights Alnylam's aggressive strategy to expand its therapeutic pipeline, while Ligand focuses on leveraging its existing portfolio. As the industry continues to innovate, these spending patterns offer a glimpse into the strategic priorities of these companies, underscoring the critical role of R&D in shaping the future of healthcare.
Research and Development: Comparing Key Metrics for Amgen Inc. and Alnylam Pharmaceuticals, Inc.
R&D Spending Showdown: Zoetis Inc. vs Ligand Pharmaceuticals Incorporated
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
Comparing Innovation Spending: Insmed Incorporated and Ligand Pharmaceuticals Incorporated
Blueprint Medicines Corporation vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Grifols, S.A. and Ligand Pharmaceuticals Incorporated
Comparing Innovation Spending: Rhythm Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated vs Xencor, Inc.: Strategic Focus on R&D Spending